Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes.

Llovet JM, Rodríguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M, Pardo A, Castells A, Cabré E, Arroyo V, Gassull MA, Rodés J.

J Hepatol. 1997 Jan;26(1):88-95.

PMID:
9148028
2.

Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, Sàbat M, Vila MC, Guarner C, Vilardell F.

Hepatology. 1997 Mar;25(3):532-6.

PMID:
9049193
3.

Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.

Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J.

Hepatology. 2002 Jan;35(1):140-8.

PMID:
11786970
4.

[Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].

Aparicio JR, Such J, Gutiérrez A, Pérez-Mateo M, Plaza J, Arroyo A.

Med Clin (Barc). 1999 Sep 11;113(7):241-5. Spanish.

PMID:
10544377
5.

Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.

Ortiz J, Vila MC, Soriano G, Miñana J, Gana J, Mirelis B, Novella MT, Coll S, Sábat M, Andreu M, Prats G, Solá R, Guarner C.

Hepatology. 1999 Apr;29(4):1064-9.

PMID:
10094947
6.

Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.

Grangé JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, Richardet JP, Vinel JP, Delisle F, Fischer D, Flahault A, Amiot X.

J Hepatol. 1998 Sep;29(3):430-6.

PMID:
9764990
7.

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.

Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, Miranda ML, Llach J, Salmerón JM, et al.

Hepatology. 1990 Oct;12(4 Pt 1):716-24.

PMID:
2210673
8.

Selective intestinal decontamination prevents spontaneous bacterial peritonitis.

Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enríquez J, Vilardell F.

Gastroenterology. 1991 Feb;100(2):477-81.

PMID:
1985045
9.

Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.

Sandhu BS, Gupta R, Sharma J, Singh J, Murthy NS, Sarin SK.

J Gastroenterol Hepatol. 2005 Apr;20(4):599-605.

PMID:
15836710
10.

[Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin].

Lecleire S, Di Fiore F, Hervé S, Goria O, Savoye G, Colin R, Lerebours E.

Presse Med. 2003 Mar 29;32(12):550-2. French.

PMID:
12714922
11.

Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.

Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa M.

Gastroenterology. 2006 Oct;131(4):1049-56; quiz 1285.

PMID:
17030175
12.
13.

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V.

Gastroenterology. 2007 Sep;133(3):818-24. Epub 2007 Jul 3.

PMID:
17854593
14.

Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.

Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G.

Clin Infect Dis. 1998 May;26(5):1066-70.

15.

Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis.

Alvarez RF, Mattos AA, Corrêa EB, Cotrim HP, Nascimento TV.

Arq Gastroenterol. 2005 Oct-Dec;42(4):256-62. Epub 2006 Jan 19.

16.

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages.

Terg R, Llano K, Cobas SM, Brotto C, Barrios A, Levi D, Wasen W, Bartellini MA.

J Hepatol. 1998 Sep;29(3):437-42.

PMID:
9764991
17.

Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis.

Lontos S, Gow PJ, Vaughan RB, Angus PW.

J Gastroenterol Hepatol. 2008 Feb;23(2):252-5. Epub 2007 Jun 7.

PMID:
17559367
18.

Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis.

Francés R, González-Navajas JM, Zapater P, Muñoz C, Caño R, Pascual S, Márquez D, Santana F, Pérez-Mateo M, Such J.

J Clin Immunol. 2007 Jul;27(4):438-44. Epub 2007 Apr 3.

PMID:
17404822
19.

Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis.

Cereto F, Molina I, González A, Del Valle O, Esteban R, Guardia J, Genescà J.

Aliment Pharmacol Ther. 2003 Mar 1;17(5):695-701.

Items per page

Supplemental Content

Write to the Help Desk